West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by West China Hospital.[1]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
Clinical trials
editIn August 2020, WestVac Biopharma started phase I clinical trials with 168 participants in China.[2]
In November, WestVac Biopharma started phase II clinical trials with 960 participants in China[3] In February 2021, WestVac Biopharma started phase IIb clinical trials with 4,000 participants in China. Later, WestVac Biopharma is no longer on phase IIb clinical trial.[4]
In June 2021, WestVac Biopharma started phase III trials with 40,000 participants including Indonesia, Kenya, and the Philippines.[5]
Children and adolescents trials
editIn August 2021 WestVac Biopharma started phase I/II trials with 600 participants for children and adolescents aged 6-17.[6]
References
edit- ^ "华西医院研发的重组新冠蛋白疫苗今日起在成都接种". www.wenjiang.gov.cn. Retrieved 13 September 2024.
- ^ "Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)". clinicaltrials.gov. United States National Library of Medicine. 8 February 2021. Retrieved 20 March 2021.
- ^ "A Phase II Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
- ^ "Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
- ^ "A Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 15 May 2021.
- ^ "Phase I/II Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 August 2021.